Synthaverse

Synthaverse Net Margin

The Net Profit Margin of Synthaverse (SVE.WA) as of Oct 17, 2026 is -47.45 %. In the previous year, Net Profit Margin was 10.52 % — a change of -550.94% (lower).

Net Margin

-47.45 %

YoY

-550.94%

Last updated:

Net Profit Margin of Synthaverse is 2025 -47.45 % . Net Profit Margin of Synthaverse was 2024 10.52 % . It decreases by -550.94% lower compared to the previous year.

Synthaverse's net margin stands at -47.4%, down from 10.3% several years earlier.

The Synthaverse Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-100.37 PLN
Jan 1, 2019
6.35 PLN
Jan 1, 2020
11.05 PLN
Jan 1, 2021
10.32 PLN
Jan 1, 2022
12.07 PLN
Jan 1, 2023
8.12 PLN
Jan 1, 2024
10.52 PLN
Jan 1, 2025
-47.45 PLN
The Synthaverse Net Margin history
YEARNet MarginYoY
-47.45 %-550.94%
10.52 %+29.60%
8.12 %-32.74%
12.07 %+16.90%
10.32 %-6.59%
11.05 %+74.09%
6.35 %-106.33%
-100.37 %-5,460.50%
1.87 %-102.90%
-64.60 %-26.12%
-87.45 %-18,089.54%
0.49 %+586.06%
0.07 %-132.87%
-0.22 %-1,708.25%
0.01 %-83.68%
0.08 %+53.64%
0.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

Net Profit Margin of Synthaverse is -47.45 % in 2025.

Net Profit Margin of Synthaverse changed from 10.52 % to -47.45 %, representing a -550.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Synthaverse since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Synthaverse with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Synthaverse

All Key Metrics — Synthaverse